vimarsana.com
Home
Live Updates
Gannex Announces Completion of the U.S. Phase I Trial of ASC
Gannex Announces Completion of the U.S. Phase I Trial of ASC
Gannex Announces Completion of the U.S. Phase I Trial of ASC43F, an In-House Developed First-in-Class Dual Targeting Fixed-dose Combination Tablet for NASH
/PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672), today announces the completion of the U.S. Phase I trial...
Related Keywords
China ,
Shanghai ,
Hong Kong ,
Handan ,
Hebei ,
Melissa Palmer ,
Hong Kong Stock Exchange ,
Ascletis Pharma Inc ,
Prnewswire Gannex Pharma Co Ltd ,
Ascletis Pharma ,
Fibroblast Growth Factor ,
Chief Scientific Officer ,
Chief Medical Officer ,
Hepatitisb Virus ,
Primary Biliary Cholangitis ,